2013年至2015年PubMed收录疼痛相关文献的统计分析与展望

目的:分析2013年至2015年Pub Med收录的疼痛相关文献的分布情况和热点,为该领域进一步研究提供参考。方法:检索Pub Med数据库2013年至2015年收录的疼痛相关文献,用Go Pub Med进行统计分析,并对比中国和世界范围内在疼痛领域发表文献的特点。阅读整理2015年中国学者发表在影响因子大于5分的期刊上的疼痛相关文献。结果:2013年至2015年Pub Med共收录疼痛相关文献97068篇。发表文献最多的国家是美国(25158篇,占全部的25.9%),其次是中国(6230篇,占全部的6.4%)。刊载疼痛文献最多的期刊是Plos One,其次是Pain和Bmj Case Rep。与世界范围内发表的疼痛相关文献相比,我国在肿瘤相关疼痛、痛觉过敏、神经痛、镇痛药相关领域的研究较多,而在慢性疼痛和头痛领域发表的文献较少。结论:近三年来疼痛领域的文献数量呈逐年上升的趋势。疼痛领域的研究主要集中在欧美、东亚等地区。目前我国疼痛领域的高质量研究主要集中在疼痛的病理生理机制、治疗新靶点等方面。     

SELF-INJURIOUS BEHAVIOUR: AN OVERVIEW OF RECENT TRENDS IN EPIDEMIOLOGICAL AND BEHAVIOURAL RESEARCH

Abstract Recent developments in epidemiological and applied behavioural research and practice are reviewed. Three key themes in applied behavioural approaches are identified and discussed: an increasing tendency to base interventions upon prior experimental analyses; the use of communication as a metaphor in understanding the function of self-injurious behaviour; a questioning of the social validity of aversive interventions.     

HIV‐1 integrase inhibitors: 2007–2008 update

In recent years, HIV‐1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the advent of a new generation of antiretroviral drugs. The development of raltegravir and other successful lead IN inhibitors has also influenced the IN inhibitor design strategy. This has led to the identification of several potent inhibitors in these last two years. Further, an increased understanding of IN structural biology has opened up novel approaches to inhibiting IN, such as targeting its multimerization or interaction with cellular cofactors. This review covers recent developments in the field of IN inhibitor design from 2007 to 2008. © 2010 Wiley Periodicals, Inc. Med Res Rev, 30, No. 6, 890–954, 2010